Mr. Yanling Cao is a founding member and Managing Director of Boyu Capital and in charge of investments and portfolio management in the healthcare sector. He currently serves on the boards of a number of leading pharmaceutical, diagnostic and healthcare service companies in China. Prior to Boyu, Mr. Cao worked as an investment professional at General Atlantic and Goldman Sachs on a wide range of strategic and financial transactions. Mr. Cao received Bachelor of Arts in Economics and Mathematics, summa cum laude, from Middlebury College.
BOARD OF DIRECTORS
Mr. Edward Hu is currently Chief Financial Officer and Chief Investment Officer at WuXi AppTec. Mr. Hu manages WuXi AppTec’s finance, investments, mergers and acquisitions, joint ventures, and new business and capability building. Mr. Hu previously served as WuXi’s chief operating officer and chief financial officer for five years until April 2014. Prior to joining WuXi in August 2007, he was a senior vice president and chief operating officer at Tanox, a biopharmaceutical company acquired by Genentech. He also held positions at Merck & Co., Inc. as a senior financial analyst and later in business and financial planning at Biogen, Inc. Mr. Hu completed his Ph.D. work, all but dissertation, in biophysics and biochemistry at Carnegie Mellon University, where he also received his M.B.A.
Bahija Jallal, Ph.D.
Chair, Board of Directors, Viela Bio
President of MedImmune & Executive Vice President, AstraZeneca
Dr. Bahija Jallal is President of MedImmune, the global biologics research and development unit of AstraZeneca. She is also Executive Vice President of AstraZeneca and is a member of its senior executive team reporting to the CEO. Dr. Jallal joined MedImmune in March 2006. Dr. Jallal serves on the Board of Anthem, Inc. and is a member of the Board of Trustees of the Johns Hopkins University and the Board of Directors of the University of Maryland Health Sciences Research Park Corporation. Dr. Jallal has authored over 70 peer-reviewed publications and has more than 15 patents. She is a member of the American Association of Cancer Research and the American Association of Science. She is also the President of the Association of Women in Science. Dr. Jallal was named the 2017 Woman of the Year by the Healthcare Businesswomen’s Association.
Dr. Ting Jia “TJ” serves as a Managing Director at Hillhouse Capital Management, where he is primarily responsible for managing the firm’s public and private investments in the life science sector. Prior to that, he worked as an investment analyst at BVF Partners LP and as a management consultant at McKinsey & Company. He received his Ph.D. in Immunology from Weill Cornell and Memorial Sloan-Kettering Cancer Center, and a B.S. in Biological Sciences from Sun Yat-sen University.
Dr. Tyrell Rivers is an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers also serves on the Board of Directors for G1 Therapeutics (GTHX), Corvidia Therapeutics and Armaron Bio Ltd and as a Board observer for several private companies.
Mr. Sean Tong is co-founder and Managing Partner of Boyu Capital and currently serves on the board of a number of publicly listed and privately held companies. Prior to Boyu, he was a Managing Director and Head of Greater China at General Atlantic LLC and Providence Equity Partners. He graduated magna cum laude from Harvard University.
Dr. Bing Yao is the CEO of Viela Bio. Bing brings more than 20 years’ experience in the biopharmaceutical industry, with a track record of leading successful discovery and development of multiple biotherapeutics. Most recently, during his tenure at MedImmune, he played key leadership roles in the development and approval of three novel biologics for autoimmune, respiratory, and immune-oncology indications respectively. Bing is on the Board of Directors for NexImmune. Bing received his Ph.D in Microbiology and Immunology from the University of Iowa, followed by postdoctoral work at Immunex.